Trials / Completed
CompletedNCT02954081
APremilast After FumaRic Acid Ester Treatment
Real-world Benefit of Apremilast Treatment of Patients With Moderate-to-severe Psoriasis After Transition From Fumaric Acid Esters
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 687 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Patient treatment preference and treatment satisfaction of physicians and patients comparing fumaric acid ester therapy with subsequent apremilast treatment
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Phase I: Fumaric acid esters. Phase II: Apremilast | Apremilast |
Timeline
- Start date
- 2017-01-26
- Primary completion
- 2022-08-15
- Completion
- 2022-08-15
- First posted
- 2016-11-03
- Last updated
- 2023-01-26
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02954081. Inclusion in this directory is not an endorsement.